Dyslipidemia characterized by high plasma triglycerides and low HDL-cholesterol is a key risk factor for cardiovascular disease. There are approximately 150 million people with this type of dyslipidemia in the G7 countries and 60 million of them are considered as high-risk patients. Lipigon Pharmaceuticals develops innovative first-in-class drugs aiming at treating these patients.
Lipigon is a lipid biology specialist company, utilizing its proprietary and unique know-how and technologies to discover and develop novel therapies for patients with lipid disorders and other cardiometabolic risk factors. Lipigon is looking for additions to our product portfolio. Please contact us for partnering proposals.
Lipigon is currently focusing on the discovery of small molecule activators of Lipoprotein lipase (LPL). Humans with lowered activity of LPL have increased dyslipidemia associated with multiple metabolic abnormalities, such as insulin resistance and/or metabolic syndrome. Lipigon believes that it, with its long experience and expert know-how about the target is perfectly suited to discover drugs that target LPL. Our lead product candidate is a first-in-class orally available small molecule designed to significantly lower elevated levels of TG, raise levels of HDL and improve other cardiometabolic risk factors.
Our mission is to provide safe and effective treatments for patients with lipid disorders and other cardiometabolic risk factors, thus making a significant improvement in the quality of life and survival of these patients.
Our vision is to build a profitable company with a sustainable pipeline of products and product candidates. The short-term goal is to select a clinical candidate in our LPL program. The long-term goal is to successfully run projects to a major value inflection point, such as proof-of-concept in man or market authorization, and to form partnerships for further development or marketing.